These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23642552)

  • 1. Posttreatment evaluation of central nervous system gliomas.
    Shiroishi MS; Booker MT; Agarwal M; Jain N; Naghi I; Lerner A; Law M
    Magn Reson Imaging Clin N Am; 2013 May; 21(2):241-68. PubMed ID: 23642552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
    Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
    J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma.
    Kim MM; Lawrence TS; Cao Y
    Semin Radiat Oncol; 2015 Jul; 25(3):172-80. PubMed ID: 26050587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
    Sharma M; Juthani RG; Vogelbaum MA
    Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas.
    Boxerman JL; Ellingson BM
    Top Magn Reson Imaging; 2015 Jun; 24(3):127-36. PubMed ID: 26049816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System.
    Weinberg BD; Gore A; Shu HG; Olson JJ; Duszak R; Voloschin AD; Hoch MJ
    J Am Coll Radiol; 2018 May; 15(5):767-771. PubMed ID: 29503151
    [No Abstract]   [Full Text] [Related]  

  • 7. Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence.
    Kim HS; Kim JH; Kim SH; Cho KG; Kim SY
    Radiology; 2010 Sep; 256(3):906-15. PubMed ID: 20634429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
    van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
    Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the volume of gliomas in the brain in FLAIR and post-contrast T1-weighted MRI sequences.
    Gurwara S; Azzawe A; Jacobs S; Ravi A; Hardjasudarma M; Toledo EG
    J La State Med Soc; 2010; 162(5):265-6. PubMed ID: 21141258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.
    Fatterpekar GM; Galheigo D; Narayana A; Johnson G; Knopp E
    AJR Am J Roentgenol; 2012 Jan; 198(1):19-26. PubMed ID: 22194475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response assessment in neuro-oncology.
    Quant EC; Wen PY
    Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging and response criteria in gliomas.
    Gerstner ER; Batchelor TT
    Curr Opin Oncol; 2010 Nov; 22(6):598-603. PubMed ID: 20689430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk of increased malignancy a reason for follow-up of low malignancy grade glioma. Early identification of high-risk patients is the key to good care].
    Smits A; Ribom D
    Lakartidningen; 2000 Sep; 97(36):3886-90. PubMed ID: 11036339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging-guided gene therapy of gliomas.
    Rueger MA; Winkeler A; Thomas AV; Kracht LW; Jacobs AH
    Handb Exp Pharmacol; 2008; (185 Pt 2):341-59. PubMed ID: 18626610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical modeling of glioma on MRI.
    Mandonnet E
    Rev Neurol (Paris); 2011 Oct; 167(10):715-20. PubMed ID: 21890155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of adult glioma is multiphasic].
    Mäenpää HO
    Duodecim; 2010; 126(14):1669-75. PubMed ID: 20804085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial end points in malignant glioma: need for effective trial design strategy.
    Brada M; Yung WK
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):11-9. PubMed ID: 10866345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroradiological response criteria for high-grade gliomas.
    Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
    Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional susceptibility-weighted imaging at 3 T using various image analysis methods in the estimation of grading intracranial gliomas.
    Hori M; Mori H; Aoki S; Abe O; Masumoto T; Kunimatsu S; Ohtomo K; Kabasawa H; Shiraga N; Araki T
    Magn Reson Imaging; 2010 May; 28(4):594-8. PubMed ID: 20233645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.